Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
The current ruling will assure the safety of the use of Ranitidine for Indian patients
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
The only definitive way to diagnose and stage lung cancers is through biopsies
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
Subscribe To Our Newsletter & Stay Updated
